Pancreatic serous cystadenoma

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Eye Cancer

Retrieved on: 
Montag, Mai 20, 2024
Uveal melanoma, MPH, Pancreatic serous cystadenoma, Patent, Tumor microenvironment, MD, Tokyo Stock Exchange, Metastasis, CD8, Code, Vaccine

Once issued, this patent is expected to expire no earlier than July 2042.

Key Points: 
  • Once issued, this patent is expected to expire no earlier than July 2042.
  • The allowed claims cover the use of MN-166 (ibudilast) for preventing, ameliorating, or minimizing metastasis of eye cancer.
  • The allowed claims specifically cover the use of MN-166 (ibudilast) for preventing, ameliorating, or minimizing metastasis of uveal melanoma.
  • We are gratified that this new patent will enhance potential value of MN-166 (ibudilast) in the oncology field.”

Ajax Therapeutics Raises $95 Million Series C Financing To Advance First-in-Class Type II JAK2 Inhibitor, AJ1-11095, Into The Clinic

Retrieved on: 
Montag, Mai 13, 2024
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Patient, Doctor of Philosophy, Eli Lilly and Company, Type, Goldman Sachs, Therapy, Disease, JAK2, Senior, MPN, JAK, Point72 Asset Management, Pancreatic serous cystadenoma, Ruxolitinib, Type 2, Polycythemia, Pharmaceutical industry

Ajax Therapeutics, Inc. , a biopharmaceutical company developing next generation JAK inhibitors for patients with myeloproliferative neoplasms (MPNs), today announced the closing of an oversubscribed $95 million Series C financing.

Key Points: 
  • Ajax Therapeutics, Inc. , a biopharmaceutical company developing next generation JAK inhibitors for patients with myeloproliferative neoplasms (MPNs), today announced the closing of an oversubscribed $95 million Series C financing.
  • Proceeds from the financing will be used to support the clinical development of Ajax’s first-in-class Type II JAK2 inhibitor, AJ1‑11095, for the treatment of myelofibrosis, as well as advancing the company’s pipeline of treatments for MPNs.
  • Additionally, AJ1-11095 has been shown in preclinical studies to maintain efficacy against MPN cells that become resistant to chronic Type I JAK2 inhibition.
  • “My lab has been studying Type II inhibition of JAK2 for over 10 years and we believe AJ1-11095 possesses the unique therapeutic properties and disease modifying effects of a highly selective and potent Type II JAK2 inhibitor and we’re excited to bring it to patients with MF.”

Ajax Therapeutics Announces FDA Clearance of IND Application for AJ1-11095, a First-in-Class Type II JAK2 inhibitor, for the Treatment of Myelofibrosis

Retrieved on: 
Montag, Mai 13, 2024
Oncology, Health, FDA, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Patient, Type, Food, Therapy, IND, Trial of the century, Disease, JAK2, FACP, MD, JAK, Medicine, Pancreatic serous cystadenoma, Ruxolitinib, Pharmaceutical industry

Ajax Therapeutics, Inc. , a biopharmaceutical company developing next generation JAK inhibitors for patients with myeloproliferative neoplasms (MPNs), today announced that it has received clearance for its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) to initiate a Phase 1clinical study of AJ1‑11095, a first-in-class Type II JAK2 inhibitor, for the treatment of patients with myelofibrosis.

Key Points: 
  • Ajax Therapeutics, Inc. , a biopharmaceutical company developing next generation JAK inhibitors for patients with myeloproliferative neoplasms (MPNs), today announced that it has received clearance for its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) to initiate a Phase 1clinical study of AJ1‑11095, a first-in-class Type II JAK2 inhibitor, for the treatment of patients with myelofibrosis.
  • “We are thrilled to obtain clearance to advance AJ1-11095 into the clinic and excited to bring this innovative new medicine to patients with myelofibrosis,” said Martin Vogelbaum, co-founder and CEO of Ajax Therapeutics.
  • “This is an important milestone for our company and our first program to enter the clinic and the first clinical study to ever evaluate a Type II JAK2 inhibitor in patients.”
    “We look forward to the clinical development of AJ1-11095 in myelofibrosis and to initiating our Phase 1 dose escalation study, AJX-101, later this year,” said David Steensma, MD, FACP, Chief Medical Officer at Ajax.
  • “As a first-in-class therapy with a unique mechanism as a Type II inhibitor of JAK2, AJ1-11095 was developed to provide a much-needed new treatment for patients with myelofibrosis by offering the potential for improved efficacy with disease modifying effects compared to existing therapies.”

TILT Biotherapeutics Presents Clinical Data on TILT-123 in Combination with KEYTRUDA® (pembrolizumab) for Ovarian Cancer at AACR 2024

Retrieved on: 
Mittwoch, April 10, 2024
Cancer, Interleukin, Pembrolizumab, Merck & Co., Pancreatic serous cystadenoma, Tumor microenvironment, Immunoglobulin E, Patient, TILT, B cell, Potyvirus, Immunomodulation, AACR, Neoplasm, Merck, Ovarian cancer, Injection, Platinum, Pharmaceutical industry

HELSINKI, Finland, April 10, 2024 (GLOBE NEWSWIRE) -- TILT Biotherapeutics (TILT), a clinical-stage biotechnology company developing cancer immunotherapies presented promising preliminary safety and efficacy data from their ongoing Phase I clinical trial (NCT05271318) in platinum resistant or refractory ovarian cancer patients at the American Association for Cancer Research (AACR) Annual Meeting 2024.

Key Points: 
  • HELSINKI, Finland, April 10, 2024 (GLOBE NEWSWIRE) -- TILT Biotherapeutics (TILT), a clinical-stage biotechnology company developing cancer immunotherapies presented promising preliminary safety and efficacy data from their ongoing Phase I clinical trial (NCT05271318) in platinum resistant or refractory ovarian cancer patients at the American Association for Cancer Research (AACR) Annual Meeting 2024.
  • Analysis of biological samples revealed insights into mechanism of action, including an immunological profile potentially predictive of clinical response.
  • The results presented at AACR 2024, along with data from other ongoing trials, underscore the promise of TILT-123 as a novel cancer therapy.
  • KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

PharmaEssentia Appoints Robert Geller, M.D. as Head of Medical and Shawn Gibbs, J.D. as Head of Legal

Retrieved on: 
Mittwoch, April 24, 2024
Research, Legal, Clinical Trials, Professional Services, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Shawn, Massachusetts Institute of Technology, University, Vion Pharmaceuticals, Optimer Pharmaceuticals, Physics, Pancreatic serous cystadenoma, Safety, Pharmacovigilance, Hematology, GE HealthCare, Grinnell College, Partnership, Alexion Pharmaceuticals, Partner, Senior, Corporate lawyer, Patient, Medicine, Multimedia, Marketing, Drug development, Harvard Medical School, Associate, Trade, Ophthalmology, Ovarian cancer, Gerber Products Company, Platinum, Strategic planning, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20240423922725/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240423922725/en/
    Dr. Robert Geller is a medical oncologist with diverse expertise across the biotechnology industry and in academia, including in drug development, medical affairs, business development and as a clinical scientist.
  • As the new Head of Medical at PharmaEssentia, Dr. Geller will be responsible for U.S. clinical operations, reporting to Chief Medical Officer, Albert Qin, M.D., Ph.D.
  • joins PharmaEssentia with extensive experience across legal affairs in the biopharmaceutical industry, including in corporate transactions, governance, compliance, litigation, regulatory matters, and strategic planning.
  • Prior, he held several legal positions with Sequirus, Inc., including most recently Executive Director, Associate General Counsel, Americas, within Commercial Development and Medical Affairs.

Ryvu Therapeutics Presents Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting

Retrieved on: 
Mittwoch, April 10, 2024
PV, MSI, PIM, MTAP, RecQ helicase, Cell, MF, Christian democracy, Safety, PARP, Pancreatic serous cystadenoma, Polycythemia vera, Colorectal cancer, PLN, Polycythemia, MPN, CRC, Collection, Research, MTA, Haematopoiesis, Three-sector model, WBC, WRN, Therapy, Ruxolitinib, PDC, Chemical substance, Splenomegaly, Neoplasm, Intellectual property, Standard of care, AACR, Drug discovery, PRMT5, Vaccine

RVU120 shows efficacy both as a monotherapy and synergistically in combination with ruxolitinib in preclinical models of myeloproliferative neoplasms, including myelofibrosis and polycythemia vera.

Key Points: 
  • RVU120 shows efficacy both as a monotherapy and synergistically in combination with ruxolitinib in preclinical models of myeloproliferative neoplasms, including myelofibrosis and polycythemia vera.
  • KRAKOW, Poland, April 10, 2024 /PRNewswire/ -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, presents preclinical data from its synthetic lethality pipeline, RVU120, and MEN1703 (SEL24) at the 2024 AACR Annual Meeting, April 5-10 in San Diego, California.
  • "We are excited to present our latest advancements in oncology therapeutics at the AACR Annual Meeting this year.
  • Strong preclinical data from our two lead synthetic lethality programs – PRMT5 and WRN – are encouraging as we make progress toward the identification of competitive clinical candidates," said Krzysztof Brzózka, Ph.D., Chief Scientific Officer of Ryvu Therapeutics.

Cellenkos® enters into Sponsored Research Agreement with Icahn School of Medicine at Mount Sinai, New York.

Retrieved on: 
Montag, April 1, 2024
Research, Pacritinib, JAK2, Bone marrow, Blood transfusion, CXCR4, Inflammation, Patient, University, Ruxolitinib, Clinical trial, CXCL12, Fedratinib, Safety, Pancreatic serous cystadenoma, University of California, Davis, MD Anderson Cancer Center, Albert Einstein Israelite Hospital, Pharmaceutical industry

Research exploring CK0804 (CXCR4-enriched, allogeneic, cord blood-derived T-regulatory cells) for treatment of myelofibrosis patients.

Key Points: 
  • Research exploring CK0804 (CXCR4-enriched, allogeneic, cord blood-derived T-regulatory cells) for treatment of myelofibrosis patients.
  • This research will be conducted under the guidance of Ronald Hoffman, MD, Albert A. and Vera G. List Professor of Medicine and Director of the Myeloproliferative Disorders Research Program at The Tisch Cancer Institute- Mount Sinai.
  • CK0804 is a novel allogeneic, CXCR4 enriched, Treg cell therapy product that utilizes Cellenkos' proprietary CRANE® technology to generate disease specific products.
  • Dr. Ronald Hoffman serves as a paid consultant for Cellenkos.

Incyte Launches The Unseen Journey to Elevate the Hidden Impact of Myeloproliferative Neoplasms (MPNs) on Patients’ Lives through Generative AI

Retrieved on: 
Donnerstag, Februar 29, 2024
Technology, Medical Devices, Software, Audio, Video, Biotechnology, General Health, Pharmaceutical, Health, Oncology, Artificial Intelligence, Pancreatic serous cystadenoma, PV, Multimedia, AI, MF, Friends, Empathy, Education International, Bone marrow, Fatigue, Patient, Family, Headache, Ruxolitinib, MPN, Brain, Medical imaging

Incyte (Nasdaq: INCY) today announced the launch of The Unseen Journey, a program that brings to life the hidden emotional and physical toll of myeloproliferative neoplasms (MPNs), a group of rare, chronic and progressive blood cancers.

Key Points: 
  • Incyte (Nasdaq: INCY) today announced the launch of The Unseen Journey, a program that brings to life the hidden emotional and physical toll of myeloproliferative neoplasms (MPNs), a group of rare, chronic and progressive blood cancers.
  • View the full release here: https://www.businesswire.com/news/home/20240229692531/en/
    The Unseen Journey highlights the stories of people living with MPNs who were asked to describe their symptoms and how they impact their lives in their own words.
  • As each patient described their symptoms and experiences, generative AI tools transformed their words into images that visually depict the patient’s most burdensome symptoms.
  • It is important for MPN patients to track their symptoms on a regular basis to help inform conversations with their health care provider.

PharmaEssentia’s BESREMi (ropeginterferon alfa-2b-njft) Now Recommended as a Preferred First-line Cytoreductive Therapy for Polycythemia Vera in Updated NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)

Retrieved on: 
Dienstag, Februar 27, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Clinical Trials, Peginterferon alfa-2a, Leukemia, Polycythemia, Safety, Hematology, MDS, NCCN, Pancreatic serous cystadenoma, Patient

National Comprehensive Cancer Network® (NCCN®) is a well-recognized, not-for-profit alliance of leading cancer centers in the United States.

Key Points: 
  • National Comprehensive Cancer Network® (NCCN®) is a well-recognized, not-for-profit alliance of leading cancer centers in the United States.
  • The updated NCCN Guidelines® were released on December 21, 2023.
  • “This is another important milestone for BESREMi as a preferred, FDA-approved option for both symptomatic low- and high-risk PV patients,” said Albert Qin, M.D., Ph.D., Chief Medical Officer at PharmaEssentia Corporation.
  • “We are encouraged by the increasing dialogue across academic and community healthcare practitioners rethinking treatment approaches given the potential of BESREMi for this myeloproliferative neoplasm.”

Ryvu Therapeutics to Present Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting

Retrieved on: 
Mittwoch, März 6, 2024
WBC, WRN, Lung cancer, RNA, Malignancy, Microsatellite instability, Proteome, Intellectual property, MMR, MPN, Glioblastoma, Neoplasm, Splenomegaly, DMPK, Phosphorylation, HDAC, STAT5, RNA-Seq, WES, Standard of care, Therapy, RecQ helicase, Phenotype, Ruxolitinib, DNA, DNA repair, Pancreatic serous cystadenoma, CDKN2A, Cancer, CRC, PIM, Arginine, MTA, Abstract, PDC, MTAP, Colorectal cancer, CRISPR, PV, MF, MSI-H, Cell, JAK, DNA mismatch repair, Medicine, Patient, Gene, PRMT5, Haematopoiesis, Mesothelioma, Pharmaceutical industry

Ryvu's partner Menarini to present data on MEN1703 (SEL24), demonstrating promising anti-tumor activity in preclinical models of myelofibrosis both as a single agent and combined with ruxolitinib.

Key Points: 
  • Ryvu's partner Menarini to present data on MEN1703 (SEL24), demonstrating promising anti-tumor activity in preclinical models of myelofibrosis both as a single agent and combined with ruxolitinib.
  • "We are excited to present our latest preclinical data at the AACR Annual Meeting, showcasing our significant progress in advancing novel small molecule therapies for oncology.
  • This year, we will present data from our most advanced preclinical project on MTA-cooperative PRMT5 inhibitors, the lead program within Ryvu's synthetic lethality pipeline.
  • Ryvu has developed potentially best-in-class MTA-cooperative PRMT5 inhibitors showing favorable drug-like properties and effective PRMT5 inhibition dependent on MTA binding.